Recent Updates
Recently added Catalysts
XTNT Positive Sentiment

Xtant Medical Announces Secondary Private Sale of Existing Shares by OrbiMed and Preliminary First Quarter 2025 Revenue Growth of 18% to 19%

Wednesday, April 16, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Xtant Medical Holdings, Inc. has announced a secondary private sale of existing shares by OrbiMed. Additionally, the company anticipates a revenue growth of 18% to 19% for the first quarter of 2025. This growth is attributed to a strategic shift towards higher-margin orthobiologics and the introduction of new products.
Price reaction · baseline $0.39 (2025-04-15 close) · hit pre-market · clean, no other XTNT news in the window
day 0 close
+1.3%
day 1
+15.1%
day 3 · peak
+22.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Xtant Medical reports a revenue growth of 18% to 19% for Q1 2025.
  • The company is supported by long-term investors backing its strategic vision.
  • New product launches are expected to enhance profit margins.

Full Press Release Details

Healthcare Focused Long-term Investors Support Strategic Vision Accelerating Shift to Higher-Margin Orthobiologics Supported by New Product Launches BELGRADE, Mont. , April 16, 2025 /PRNewswire/ — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused

Frequently Asked Questions

What revenue growth is Xtant Medical expecting for Q1 2025?

Xtant Medical anticipates a revenue growth of 18% to 19% for Q1 2025.

Who is supporting Xtant Medical's strategic vision?

Long-term investors, including OrbiMed, are supporting Xtant Medical's strategic vision.

What is the focus of Xtant Medical's new product launches?

The new product launches are aimed at accelerating the shift to higher-margin orthobiologics.

What type of company is Xtant Medical?

Xtant Medical is a global medical technology company.

ShareAdd on Google
Tags: XTNT Viatris Investor Conferences Healthcare Xtant Medical OrbiMed revenue growth orthobiologics Q1 2025
Last updated: Apr 16, 2025

Biotech snapshot

Cash runway
$10M liquidity · $2M/mo burn
~4 mo
High dilution risk